breast cancer – Medxy AI

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY 09/07/2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.

Clinical Updates Wellness & Lifestyle

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

By MedXY 09/06/2025

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial strain and cardiac biomarkers suggest a potential role in cardioprotection.

Clinical Updates Wellness & Lifestyle

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

By MedXY 09/04/2025

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast cancer survivors.

Medical News Wellness & Lifestyle

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger

By MedXY 08/23/2025

Breast cancer is the most common cancer among women, with 90% of patients belonging to high-risk groups. This article explores five major risk factors, early detection strategies, and lifestyle changes crucial for prevention.

Clinical Updates Wellness & Lifestyle

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.

Clinical Updates Wellness & Lifestyle

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

By MedXY 08/21/2025

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especially in postmenopausal women.

Clinical Updates Wellness & Lifestyle

Extending Endocrine Treatment Duration for Early Breast Cancer

By MedXY 08/19/2025

This article reviews a patient-level meta-analysis on prolonging endocrine therapy for early breast cancer in postmenopausal women, focusing on the benefits of additional aromatase inhibitor treatment after five years of initial therapy.

Clinical Updates Wellness & Lifestyle

Advancing Breast Cancer Detection: AI Identifies Missed Interval Cancers on Mammograms

By MedXY 08/18/2025

A recent study shows that an AI system can detect interval breast cancers missed by radiologists on mammograms, potentially improving early diagnosis and screening outcomes in women with dense breasts.

Medical News Wellness & Lifestyle

Breast Nodules: How Close Are They to Breast Cancer?

By MedXY 08/07/2025

This article explores the relationship between breast nodules and breast cancer, addressing common concerns and offering actionable health insights.

Clinical Updates Wellness & Lifestyle

First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance

By MedXY 08/07/2025

Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profiles.